

Homocysteine as a potential predictive factor for high major adverse cardiovascular events risk in female patients with premature acute coronary syndrome

Mei Wei

The First Hospital of Hebei Medical University

Le Wang

Tianjin Chest Hospital

Yongsheng Liu

The First Hospital of Hebei Medical University

Mingqi Zheng

The First Hospital of Hebei Medical University

Fangfang Ma

The First Hospital of Hebei Medical University

Yanchao Qi

The First Hospital of Hebei Medical University

Gang Liu (✉ ganshang8762504113@163.com)

The First Hospital of Hebei Medical University <https://orcid.org/0000-0001-7842-3933>

Research article

Keywords: Homocysteine, acute coronary syndrome, major adverse cardiovascular events, female, premature

Posted Date: August 31st, 2019

DOI: <https://doi.org/10.21203/rs.2.13695/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Medicine on November 1st, 2019. See the published version at <https://doi.org/10.1097/MD.000000000018019>.

Abstract

Background We aimed to investigate correlation of homocysteine (Hcy) level with clinical characteristics, and explore its predictive value for major adverse cardiovascular events (MACE) risk in female patients with premature acute coronary syndrome (ACS).

Methods Serum Hcy level was detected from 1,299 female patients with premature ACS. According to the tertile of Hcy level, patients were divided into three groups: lowest tertile group (≤ 9.1 $\mu\text{mol/L}$), middle tertile group ($9.2\sim 11.6$ $\mu\text{mol/L}$) and highest tertile group (>11.6 $\mu\text{mol/L}$). MACE incidence was recorded and MACE-free survival was calculated with the median follow-up duration of 28.3 months.

Results Increased Hcy correlated with older age ($P < 0.001$), higher creatinine level ($P < 0.001$) and enhanced uric acid level ($P = 0.001$), while reduced fasting glucose concentration ($P < 0.001$). MACE incidence was 10.7% and it was highest in highest tertile group (22.1%), followed by middle tertile group (7.7%) and lowest tertile group (2.4%) ($P < 0.001$). Receiver operating characteristic curve showed that Hcy distinguished MACE patients from non-MACE patients with the area under the curve of 0.789 (95% CI: 0.742-0.835). Kaplan-Meier curves revealed that MACE-free survival was shortest in Hcy highest tertile group, followed by middle tertile group and lowest tertile group ($P < 0.001$). Multivariate Cox's analyses further showed that higher Hcy level was an independently predictive factor for poor MACE-free survival (middle tertile vs. lowest tertile ($P = 0.001$, HR: 3.615, 95% CI: 1.661-7.864); highest tertile vs. lowest tertile ($P < 0.001$, HR: 11.023, 95% CI: 5.356-22.684)).

Conclusion Hcy serves as a potential predictive factor for increased MACE risk in female patients with premature ACS.

Background

Coronary heart disease (CHD) is the leading cause of global mortality and morbidity in males as well as in females [1]. As one of the most common types of CHD, acute coronary syndrome (ACS) is a group of disease conditions including ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) and unstable angina [2]. Although the rapid improvement has been achieved in ACS management with the use of adjunctive pharmacotherapy (specifically novel antiplatelets and anticoagulants), advanced percutaneous coronary intervention (PCI) procedures with drug-eluting stents, as well as coronary artery bypass grafting (CABG), differences in mortality between males and females still exists [2, 3]. The possible causes for worse prognosis in females are multifactorial, which partly include higher baseline prevalence of risk factors for cardiovascular disease and insufficient awareness on ACS in females that results in a delayed treatment plan and poorer access to care [3–5]. Therefore, investigating additional and convincing biomarkers in female ACS patients, particularly in female patients with premature ACS, to monitor disease progression and predict prognosis is necessary.

Homocysteine (Hcy) is a naturally occurring non-proteogenic, sulfur-containing amino acid derived from methionine metabolism through methyl group metabolism [6]. It could not only influence endothelial

function to cause a prothrombotic environment, platelet activation and endothelial leukocyte interactions, but also increase inflammatory responses, which has been considered as a risk factor for the development of atherosclerosis and has a potential effect in the prediction of risk for developing CHD [7, 8]. Furthermore, a previous study discloses that plasma Hcy is highly expressed in young patients with premature CHD compared to older patients, and it serves as an independent predictor for the age of onset of CHD [9]. Considering that the role of Hcy as a potential risk factor in CHD (including premature CHD), we hypothesized that Hcy plays an important role in female patients with premature ASC. However, information about it is still largely unknown. Therefore, we carried out this study with the purpose for investigating the correlation of Hcy level with clinical characteristics, and exploring its predictive value for major adverse cardiovascular events (MACE) risk in female patients with premature ACS.

Methods

Patients

A total of 1,299 female patients with premature ACS in our hospital from March 1, 2014 to December 31, 2017 were screened. The screening criteria were as follows: (1) diagnosed as ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or unstable angina (UA), according to the World Health Organization definition [10]; (2) female with age at diagnosis < 55 years; (3) agreed to the study protocol and the schedule of clinical and angiographic follow-up. The exclusion criteria included severe cardiomyopathy, severe valvular disease requiring surgical treatment, malignant neoplasms, systemic immune disease, severe liver and kidney dysfunction. Finally, a total of 1,102 female patients with premature ACS were eligible and analyzed in the present study. Written informed consent was obtained from each patient, and this research was approved by the Institutional Review Board of our hospital.

Data collection and sample detection

Clinical characteristics (such as age, smoking status, hypertension, diabetes, family history of coronary heart disease (CHD), history of stroke, CHD, old myocardial infarction (OMI), PCI, CABG, etc.) were recorded for each patient. Blood samples were collected from all patients on an empty stomach at the next morning after admission. Biochemical indicators (such as total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), very low-density lipoprotein (VLDL), triglycerides, apolipoprotein (a), apolipoprotein (b), lipoprotein (a), fibrinogen, high-sensitivity C-reactive protein (hs-CRP), fasting glucose, creatinine, uric acid, etc.) were measured as hospital usual practice and were documented. Meanwhile, left ventricular ejection fraction (LVEF) was measured by Ultrasound Cardiogram and was recorded as well. Most importantly, the serum was isolated from the blood sample by centrifugation, and the serum Hcy level was detected by a fully automated analyzer.

Coronary angiography and treatment

All patients underwent coronary angiography using standard Judkins technique after admission. And the coronary angiography findings, such as numbers of stenosis vessels, lesion location, etc., were also recorded. The appropriate treatments, such as pain relief, antiplatelet, anticoagulation and reperfusion therapy (PCI, CABG or thrombolytic therapy), were administered to the patients according to the clinical status. And the reperfusion therapy type and drugs used after operation were documented as well.

Follow-up and assessment

After discharge from hospital, patients were followed up every 3~6 months (or as clinically indicated) by telephone and outpatient visits. The median follow-up duration was 28.3 months (interquartile range: 20.0–38.8 months) with the deadline of 2018/12/31. During the follow-up, MACE occurred among patients were recorded, which was defined as a composite of cardiac death, acute myocardial infarction (AMI) and UA. The cardiac death was defined as sudden death with no other explanation available, death due to arrhythmia or after MI or heart failure, or death caused by heart surgery or endocarditis [11]. The AMI was defined in line with Third Universal Definition of Myocardial Infarction [12], and the UA was defined according to the World Health Organization definition [10]. And the MACE-free survival was defined as the time interval from the date of initial therapy for ACS to the date of first MACE occurred. Patients who not experienced MACE were censored on the last follow-up date.

Statistical analysis

In the analysis of this study, patients were categorized into three groups based on the tertile values of Hcy level as follows: lowest tertile: ≤ 9.1 $\mu\text{mol/L}$; middle tertile: $9.2\sim 11.6$ $\mu\text{mol/L}$; highest tertile: >11.6 $\mu\text{mol/L}$. Continuous variables were determined by the Shapiro-Wilk test for the normality. The normal-distributed continuous variable was displayed as mean \pm standard deviation (SD), while the skewed-distributed continuous variable was displayed as median and interquartile range (IQR). The categorized variable was described as count (percentage). comparison of continuous variable among tertile groups was determined by the one-way analysis of variance (ANOVA) (for normal-distributed variable) or by the Kruskal-Wallis H test (for skewed-distributed variable); comparison of skewed-distributed continuous variable between patients with MACE and patients without MACE was determined by the Wilcoxon rank sum test; comparison of categorized variable among tertile groups was determined by Chi-square test. The performance of the variable in predicting MACE risk was assessed by the receiver operating characteristic (ROC) curve and the derived area under the curve (AUC). The MACE-free survival was displayed by the Kaplan-Meier (K-M) curves and was determined by the log-rank test among tertile groups. The factors predicting the MACE-free survival were assessed by univariable and multivariable Cox's proportional hazard regression model analyses. All tests were 2-sided, and P value <0.05 was considered statistically significant. All statistical analyses were performed in SPSS software version 20.0

(IBM Corporation, Armonk, NY, USA), and all figures were plotted by the GraphPad Prism software version 7.02 (GraphPad Software Inc., San Diego, CA, USA).

Results

Baseline characteristics

The mean age of 1102 female patients with premature ACS was 51.5 ± 3.7 years (*Table 1*). There were 916 (83.1%) patients diagnosed as UA, 137 (12.4%) patients diagnosed as NSTEMI as well as 49 (4.5%) patients diagnosed as STEMI. And the median value of LVEF was 62.00% (58.00%–65.00%). According to the coronary angiography findings, the number of patients with artery lesion in LM, LAD, LCX and RCA was 40 (3.6%), 373 (33.8%), 141 (12.8%) and 176 (16.0%) respectively. As for treatment, there were 59 (5.4%) patients received CABG, 556 (50.4%) patients received PCI and 487 (44.2%) patients received thrombolytic therapy. Detailed information about other characteristics were shown in *Table 1*.

Association of Hcy with clinical characteristics

According to the tertile of Hcy level, we divided all patients into three groups, including lowest tertile group, middle tertile group and highest tertile group. Increased Hcy level was correlated with older age ($P < 0.001$), higher creatinine level ($P < 0.001$) and enhanced uric acid level ($P = 0.001$), while reduced fasting glucose concentration ($P < 0.001$). However, there was no difference in other clinical characteristics among these three groups (All $P > 0.05$) (*Table 2*).

Association of Hcy with MACE incidence

In a total of 1102 female patients with premature ACS, there were 118 (10.7%) patients occurring MACE during follow-up, which included 100 (9.1%) patients with UA alone, 10 (0.9%) patients with AML alone, 6 (0.5%) patients with UA and AML, as well as 2 (0.2%) cardiac deaths (*Table 3*). Increased Hcy level was associated with higher MACE incidence ($P < 0.001$), as well as elevated UA incidence ($P < 0.001$), raised AML incidence ($P = 0.042$), as well as boosted UA and AML incidence ($P = 0.029$). However, no correlation of Hcy level with cardiac death was discovered in these female patients with premature ACS ($P = 0.598$).

The predictive value of Hcy for MACE risk and its correlation with MACE-free survival

There were 118 MACE patients and 984 non-MACE patients, and Hcy level was higher in MACE patients (median value: 17.15 (10.80 – 21.43) $\mu\text{mol/L}$) compared to non-MACE patients (median value: 10.10 (8.20 – 12.10) $\mu\text{mol/L}$) ($P < 0.001$) (*Figure 1A*). Further ROC curve showed that Hcy level could distinguish MACE patients from non-MACE patients with AUC of 0.789 (95% CI: 0.742–0.835). The sensitivity and

specificity was 51.7% and 95.0% respectively at the best cut of point (Hcy level value: 16.85 $\mu\text{mol/L}$) (*Figure 1B*). In order to explore the correlation of MACE-free survival with Hcy level in female patients with premature ACS, K-M curve was performed and revealed that MACE-free survival was shortest in Hcy highest tertile group, followed by middle tertile group and then lowest tertile group ($P < 0.001$) (*Figure 1C*).

Potential factors affecting MACE-free survival

To investigate potential factors predicting MACE-free survival in female patients with premature ACS, univariate Cox's proportional hazard regression model analyses was performed, which disclosed that higher level of Hcy was associated with worse MACE-free survival in female patients with premature ACS (middle tertile of Hcy level vs. lowest tertile of Hcy level ($P = 0.003$, HR: 3.160, 95% CI: 1.491–6.698); highest tertile of Hcy level vs. lowest tertile of Hcy level ($P < 0.001$, HR: 9.441, 95% CI: 4.739–18.807)). Meanwhile, diagnosis of NSTEMI ($P = 0.008$), smoke ($P = 0.038$), high creatinine level ($P = 0.024$), location of artery lesion at LAD (vs. others) ($P < 0.001$), treatment of CABG ($P = 0.013$), treatment of PCI ($P < 0.001$) and clopidogrel use after surgery ($P = 0.008$) were also correlated with shorter MACE-free survival in female patients with premature ACS (*Table 4*). Further multivariate Cox's proportional hazard regression model analyses showed that higher level of Hcy was an independently predictive factor for poor MACE-free survival (middle tertile of Hcy level vs. lowest tertile of Hcy level ($P = 0.001$, HR: 3.615, 95% CI: 1.661–7.864); highest tertile of Hcy level vs. lowest tertile of Hcy level ($P < 0.001$, HR: 11.023, 95% CI: 5.356–22.684)). Meanwhile, diagnosis of NSTEMI ($P = 0.047$), high Hs-CRP ($P = 0.044$) as well as treatment of PCI ($P = 0.018$) also could independently predict poor MACE-free survival in female patients with premature ACS.

Discussion

The underlying pathophysiology of ACS is coronary atherosclerotic plaque ruptures or surface erosion to induce thrombosis or vasospasm, thereby decreasing blood flow to a part of heart musculature and causing a sudden decrease in myocardial oxygen supply [2]. Although ACS is a kind of commonly diagnosed disease and the leading cause of death globally in males as well as females, greater mortality rates after hospital discharge have been reported among female patients with premature ACS (aged 55 years or younger) compared with males of the same age [5, 13–15]. For instance, a previous study enrolling over 91,088 ACS patients discloses that young females (<50 years old) present with a higher risk of in-hospital mortality compared to male patients with similar age [13]. Another study recruits 1163 patients with premature ACS and illustrates that female patients with premature ACS appear to have a higher incidence of rehospitalization compared to male patients with premature ACS [5]. Therefore, these previous studies indicate that female patients with premature ACS present with a worse prognosis than male patients with premature ACS. With regard to this, exploration of additional and convincing biomarkers for supervising diseases progression and predicting prognosis in female patients with ACS, particularly in female patients with premature ACS, is vital.

According to previous studies, Hcy could not only directly damage blood vessels, but also indirectly increase the affinity of lipoprotein (a) for fibrin, promote vascular smooth muscle cells and inhibit endothelial cell growth to trigger and exacerbate atherosclerosis [16–18]. In addition, Hcy also contributes to the processes of inflammation. For instance, increased Hcy level plays a chemotactic role for leukocytes to leukocyte mobilization in ischemic conditions, and it also upregulates cathepsin to subsequent promote nuclear translocation of extracellular signal regulated kinase 1/2 (ERK1/2) and phosphorylation of signal transducer and activator of transcription 1 (STAT1), thereby medicating vascular endothelial inflammation that is an early and vital event in the development of vascular disease, including ACS [19, 20]. Therefore, Hcy may be a potential role in the development and progression of ACS.

Although great attention has been paid in the underlying mechanism of Hcy in ASC, few studies are focusing on the correlation of Hcy level with clinical characteristics in ASC patients, particularly in female patients with premature ACS. Hence, we enrolled 1102 female patients with premature ACS and investigated the correlation of Hcy with clinical characteristics in these patients. The results showed that evaluated Hcy level was associated with older age, increased creatinine and enhanced uric acid, but with decreased fasting glucose in female patients with premature ACS. The possible reasons were as follows: (1) Hcy could decrease nitric oxide, increase transforming growth factor b (TGF-b) signaling pathway as well as promote reactive oxygen species (ROS) accumulation to affect nerve demyelination in the central and peripheral nervous systems, thereby served as a risk factor for peripheral neuropathy [21–23]. Meanwhile, peripheral neuropathy itself had been disclosed to be related with gait speed decline in older adults [23, 24]. Thus, increased Hcy level might be correlated with older age in female patients with premature ACS. (2) Hcy had been documented as an independent risk factor for cardiovascular diseases [25]. Meanwhile, creatinine and uric acid were also the important risk factors for cardiovascular diseases [26]. Hence, increased Hcy level might be indirectly associated with higher concentrations of creatinine and uric acid in female patients with premature ACS. (3) high level of Hcy might be correlated with increased uric acid (that promoted emergence of free oxygen species and state of oxidative stress), which was closely related to high metabolism, thereby promoted glycometabolism and decreased fasting glucose in female patients with premature ACS.

Currently, concerns have been raised regarding an increased risk of MACE in ACS patients. Based on previous studies, the incidence of MACE is 9% and 8% in female ACS patients and male ACS patients after 12-month follow-up, respectively [5]. Whereas there is a total of 35% of the incidence of MACE in ACS patients after 24-month follow-up [27]. Although there were several studies focusing on the incidence of MACE in ACS patients, little was known about the occurrence of MACE in patients with premature ACS, particular in female patients with premature ACS. In this study, we discovered that the MACE incidence was 10.7% in female patients with premature ACS with a median follow-up duration of 28.3 months, which was lower compared to those previous study. The major explanation might that the MACE incidence has been reported to be increased in ASC patients whith age of 65 years or older, while all patients enrolled in the present study were young with age< 55 years who presented with better resilience and stronger immunity compared to older patients, thus the incidence of MAEC was relatively lower in female patients with premature ACS enrolled in this study compared to ASC patients in previous studies [2].

Subsequently, we further explored the impact of Hcy on the MACE risk in female patient with premature ACS, and we found that higher Hcy level was correlated with increased MACE incidence, and it presented with a good predictive value for MACE risk with AUC of 0.789 (95% CI: 0.742–0.835). meanwhile, K-M curve revealed that MACE-free survival was shortest in Hcy highest tertile group, followed by middle tertile group and then lowest tertile group. The possible explanations were as follows: (1) Hcy enhanced the affinity of lipoprotein (a) for fibrin, induced vascular smooth muscle cells and reduced endothelial cell growth to accelerate thrombosis and vasospasm, thereby cause a high risk of MACE in female patients with premature ACS. (2) Hcy was involved in the vascular inflammation, which contributed to the decrease of blood flow and the reduction of myocardial oxygen supply, thereby increasing MACE occurrence in female patients with premature ACS. Although there was no evidence about the influence of Hcy on MACE incidence in female patients with premature ACS, there are several previous studies focusing on the role of Hcy in premature ACS. Compared to these previous studies, the results in this study had the similar trend about the role of Hcy in ASC. For example, a Chinese prospective cohort study enrolls 2,009 participants who are free from stroke, CHD and cancer (with the follow-up duration of 11.95 years), and reveals that the participants with Hcy >9.47 micromol/L present with a 2.3-fold risk for cardiovascular events, and participants with Hcy >11.84 micromol/L present with a 2.4-fold risk for death, suggesting that Hcy is associated with high risk of cardiovascular events and all-cause mortality in Asian populations [28]. In addition, another previous study discloses that Hcy level is higher in young patients (<56 years old) who have the combined event (including ACS, ischemic stroke and cardiac death) during follow-up compared to those free of the event, and high Hcy level at admission acts as a potential predictive factor for worse late cardiac events in patients with premature ACS [29].

Interesting results were discovered in this study, while some limitations still existed. This study was a single-center study, and all patients enrolled were from our hospital, which might cause selection bias. Thus, further study with more patients from multicenter is needed. Furthermore, the underlying mechanism of Hcy on MACE in female premature ASC is still unclear. Furthermore, the follow-up duration with the median value of 28.3 months (interquartile range: 20.0–38.8 months) in this study was relatively short, the effect of Hcy on long-term MACE risk was not investigated. Thus, further study with longer follow-up period is necessary.

In conclusion, Hcy serves as a potential predictive factor for increased MACE risk in female patients with premature ACS.

Abbreviations

Hcy: homocysteine; ACS: acute coronary syndrome; CHD: coronary heart disease; STEMI: ST-elevation myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; MACE: major adverse cardiovascular events; NSTEMI: non-ST-segment elevation myocardial infarction; OMI: old myocardial infarction; HDL: high density lipoprotein; LDL: low density lipoprotein; VLDL: very low-density lipoprotein; hs-CRP: high-sensitivity C-reactive protein; LVEF: left ventricular ejection fraction;

AMI: acute myocardial infarction; SD: standard deviation; IQR: interquartile range; ROC: receiver operating characteristic; AUC: area under the curve

Declarations

Ethics approval and consent to participate

Written informed consent was obtained from each patient, and this research was approved by the Institutional Review Board of The First Hospital of Hebei Medical University.

Consent for publication

Not applicable.

Availability of data and material

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by Key Project of Hebei Science and Technology Support Plan (No. 16277707D), Natural Science Foundation of Hebei Province (No. H2017206358) and Key Research and Development Plan of Hebei Province, Big Health Service and Biomedical Speciality (No. 17277754D).

Authors' contributions

GL contributed to conception and design, LW and YQ contributed to the acquisition of data, MW, LW and YL drafted the article, MZ, FM, YQ and GL revised it critically for important intellectual content; and all authors approved the final version to be published.

Acknowledgements

Not applicable.

References

- 1.Khera AV, Kathiresan S: Genetics of coronary artery disease: discovery, biology and clinical translation. *Nature reviews Genetics*.2017; 18(6):331–344.
- 2.Singh A, Grossman SA: *Acute Coronary Syndrome*. In: *StatPearls*. edn. Treasure Island (FL); 2019.
- 3.Pelletier R, Humphries KH, Shimony A, Bacon SL, Lavoie KL, Rabi D *et al*: Sex-related differences in access to care among patients with premature acute coronary syndrome. *CMAJ: Canadian Medical Association journal = journal de l'Association medicale canadienne*.2014; 186(7):497–504.
- 4.Janion-Sadowska A, Sielski J, Gierlotka M, Nowalany-Kozielska E, Janion M, Polonski L: Gender-related differences in clinical course, therapeutic approach and prognosis in patients with non-ST segment elevation myocardial infarction. *Kardiologia polska*.2011; 69(8):784–792.
- 5.Pelletier R, Choi J, Winters N, Eisenberg MJ, Bacon SL, Cox J *et al*: Sex Differences in Clinical Outcomes After Premature Acute Coronary Syndrome. *The Canadian journal of cardiology*.2016; 32(12):1447–1453.
- 6.Behera J, Bala J, Nuru M, Tyagi SC, Tyagi N: Homocysteine as a Pathological Biomarker for Bone Disease. *Journal of cellular physiology*.2017; 232(10):2704–2709.
- 7.Oudi ME, Aouni Z, Mazigh C, Khochkar R, Gazoueni E, Haouela H *et al*: Homocysteine and markers of inflammation in acute coronary syndrome. *Experimental and clinical cardiology*.2010; 15(2):e25–28.
- 8.Saadeddin SM, Habbab MA, Ferns GA: Markers of inflammation and coronary artery disease. *Medical science monitor: international medical journal of experimental and clinical research*.2002; 8(1):RA5–12.
- 9.Kawashiri M, Kajinami K, Nohara A, Yagi K, Inazu A, Koizumi J *et al*: Plasma homocysteine level and development of coronary artery disease. *Coronary artery disease*.1999; 10(7):443–447.
- 10.Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mahonen M, Ngu Blackett K *et al*: World Health Organization definition of myocardial infarction: 2008–09 revision. *International journal of epidemiology*.2011; 40(1):139–146.
- 11.Kim JM, Stewart R, Lee YS, Lee HJ, Kim MC, Kim JW *et al*: Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial. *Jama*.2018; 320(4):350–358.
- 12.Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD *et al*: Third universal definition of myocardial infarction. *European heart journal*.2012; 33(20):2551–2567.
- 13.Zhang Z, Fang J, Gillespie C, Wang G, Hong Y, Yoon PW: Age-specific gender differences in in-hospital mortality by type of acute myocardial infarction. *The American journal of cardiology*.2012; 109(8):1097–1103.

14. Izadnegahdar M, Singer J, Lee MK, Gao M, Thompson CR, Kopec J *et al*: Do younger women fare worse? Sex differences in acute myocardial infarction hospitalization and early mortality rates over ten years. *Journal of women's health*.2014; 23(1):10–17.
15. Vaccarino V, Parsons L, Peterson ED, Rogers WJ, Kiefe CI, Canto J: Sex differences in mortality after acute myocardial infarction: changes from 1994 to 2006. *Archives of internal medicine*.2009; 169(19):1767–1774.
16. Sreckovic B, Sreckovic VD, Soldatovic I, Colak E, Sumarac-Dumanovic M, Janeski H *et al*: Homocysteine is a marker for metabolic syndrome and atherosclerosis. *Diabetes & metabolic syndrome*.2017; 11(3):179–182.
17. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R *et al*: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. *Proceedings of the National Academy of Sciences of the United States of America*.1994; 91(14):6369–6373.
18. Harpel PC, Chang VT, Borth W: Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. *Proceedings of the National Academy of Sciences of the United States of America*.1992; 89(21):10193–10197.
19. Dudman NP: An alternative view of homocysteine. *Lancet*.1999; 354(9195):2072–2074.
20. Leng YP, Ma YS, Li XG, Chen RF, Zeng PY, Li XH *et al*: l-Homocysteine-induced cathepsin V mediates the vascular endothelial inflammation in hyperhomocysteinaemia. *British journal of pharmacology*.2018; 175(8):1157–1172.
21. Saperstein DS, Barohn RJ: Peripheral Neuropathy Due to Cobalamin Deficiency. *Current treatment options in neurology*.2002; 4(3):197–201.
22. Leishear K, Boudreau RM, Studenski SA, Ferrucci L, Rosano C, de Rekeneire N *et al*: Relationship between vitamin B12 and sensory and motor peripheral nerve function in older adults. *Journal of the American Geriatrics Society*.2012; 60(6):1057–1063.
23. Vidoni ML, Pettee Gabriel K, Luo ST, Simonsick EM, Day RS: Vitamin B12 and Homocysteine Associations with Gait Speed in Older Adults: The Baltimore Longitudinal Study of Aging. *The journal of nutrition, health & aging*.2017; 21(10):1321–1328.
24. Strotmeyer ES, de Rekeneire N, Schwartz AV, Faulkner KA, Resnick HE, Goodpaster BH *et al*: The relationship of reduced peripheral nerve function and diabetes with physical performance in older white and black adults: the Health, Aging, and Body Composition (Health ABC) study. *Diabetes care*.2008; 31(9):1767–1772.

25. Virdis A, Ghiadoni L, Salvetti G, Versari D, Taddei S, Salvetti A: Hyperhomocyst(e)inemia: is this a novel risk factor in hypertension? *Journal of nephrology*.2002; 15(4):414–421.
26. Cibickova L, Karasek D: [Uric acid as a risk factor for cardiovascular diseases]. *Vnitřní lékařství*. 62(11):919–923.
27. Pastorello EA, Farioli L, Losappio LM, Morici N, Di Biase M, Nichelatti M *et al*: Serum tryptase detected during acute coronary syndrome is significantly related to the development of major adverse cardiovascular events after 2 years. *Clinical and molecular allergy: CMA*.2015; 13(1):14.
28. Sun Y, Chien KL, Hsu HC, Su TC, Chen MF, Lee YT: Use of serum homocysteine to predict stroke, coronary heart disease and death in ethnic Chinese. 12-year prospective cohort study. *Circulation journal: official journal of the Japanese Circulation Society*.2009; 73(8):1423–1430.
29. Martin-Herrero F, Martin-Moreiras J, Pabon P, Sanchez PL, Morinigo-Munoz JL, Jimenez-Candil J *et al*: Homocysteine and outcome in young patients with acute coronary syndromes. *International journal of cardiology*.2007; 118(2):183–188.

Tables

Table 1 Baseline characteristics of female patients with premature ACS

Items	Female patients with premature ACS (N=1102)
Age (years), mean±SD	51.5±3.7
Diagnosis, No. (%)	
UA	916 (83.1)
NSTEMI	137 (12.4)
STEMI	49 (4.5)
Smoke status, No. (%)	225 (20.4)
Hypertension, No. (%)	725 (65.8)
Diabetes, No. (%)	350 (31.8)
Family history of CHD, No. (%)	219 (19.9)
History of stroke, No. (%)	83 (7.5)
History of OMI, No. (%)	44 (4.0)
History of PCI, No. (%)	95 (8.6)
History of CABG, No. (%)	6 (0.5)
LVEF (%), median (IQR)	62.00 (58.00-65.00)
Biochemical indexes, median (IQR)	
Total cholesterol (mmol/L)	4.71 (3.98-5.42)
HDL (mmol/L)	1.13 (0.96-1.32)
LDL (mmol/L)	3.09 (2.41-3.75)
VLDL (mmol/L)	0.41 (0.25-0.61)
Triglyceride (mmol/L)	1.57 (1.12-2.20)
Apolipoprotein (a) (g/L)	1.27 (1.14-1.41)
Apolipoprotein (b) (g/L)	1.02 (0.85-1.23)
Lipoprotein (a) (mg/dL)	26.45 (10.30-75.53)
Fibrinogen (mg/dL)	3.26 (2.89-3.70)
Hs-CRP (mg/L)	1.53 (0.63-3.95)
Fasting glucose (mmol/L)	5.47 (4.91-7.11)
Creatinine (μmol/L)	56.00 (50.00-63.00)
Uric acid (μmol/L)	269.00 (227.75-320.25)
Coronary angiography findings, No. (%)	
Number of disease vessel	
Normal	64 (5.8)
One-vessel disease	464 (42.1)
Two-vessel disease	265 (24.1)
Three-vessel disease	309 (28.0)
Location of artery lesion	
LM	40 (3.6)
LAD	373 (33.8)
LCX	141 (12.8)
RCA	176 (16.0)

Treatment, No. (%)	
CABG	59 (5.4)
PCI	556 (50.4)
Thrombolytic therapy	487 (44.2)
Drugs used after surgery, No. (%)	
Aspirin	1049 (95.2)
Clopidogrel	719 (65.2)
Statins	1007 (91.4)
Nitrate	468 (42.5)
ACEI	467 (42.4)
Beta blocker	727 (66.0)
Calcium antagonist	316 (28.7)

ACS, acute coronary syndromes; SD, standard deviation; UA, unstable angina; NSTEMI,

Table 2 Correlation of Hcy with clinical characteristics

Items	Lowest tertile (≤ 9.1 $\mu\text{mol/L}$)	Middle tertile (9.2-11.6 $\mu\text{mol/L}$)	Highest tertile (> 11.6 $\mu\text{mol/L}$)	<i>P</i> value
No.	374	362	366	
Age (years), mean \pm SD	50.9 \pm 4.2	51.9 \pm 3.4	51.7 \pm 3.3	<0.001
Diagnosis, No. (%)				0.672
UA	305 (81.6)	308 (85.1)	303 (82.8)	
NSTEMI	53 (14.2)	38 (10.5)	46 (12.6)	
STEMI	16 (4.3)	16 (4.4)	17 (4.6)	
Smoke status, No. (%)	64 (17.1)	75 (20.7)	86 (23.5)	0.097
Hypertension, No. (%)	230 (61.5)	249 (68.8)	246 (67.2)	0.089
Diabetes, No. (%)	134 (35.8)	110 (30.4)	106 (29.0)	0.106
Family history of CHD, No. (%)	68 (18.2)	69 (19.1)	82 (22.4)	0.317
History of stroke, No. (%)	23 (6.1)	34 (9.4)	26 (7.1)	0.232
History of OMI, No. (%)	11 (2.9)	14 (3.9)	19 (5.2)	0.292
History of PCI, No. (%)	33 (8.8)	28 (7.7)	34 (9.3)	0.745
History of CABG, No. (%)	3 (0.8)	0 (0.0)	3 (0.8)	0.229
LVEF (%), median (IQR)	62.0 (58.0-65.0)	62.0 (58.0-65.0)	61.0 (58.0- 65.0)	0.200
Biochemical indexes, median (IQR)				
Total cholesterol (mmol/L)	4.68 (3.97-5.40)	4.74 (4.02-5.45)	4.72 (3.96- 5.40)	0.874
HDL (mmol/L)	1.11 (0.95-1.33)	1.15 (0.99-1.32)	1.12 (0.94- 1.30)	0.314
LDL (mmol/L)	3.06 (2.37-3.76)	3.13 (2.46-3.84)	3.07 (2.42- 3.64)	0.744
VLDL (mmol/L)	0.39 (0.23-0.59)	0.40 (0.26-0.58)	0.43 (0.26- 0.64)	0.334
Triglyceride (mmol/L)	1.54 (1.11-2.31)	1.58 (1.10-2.17)	1.59 (1.14- 2.15)	0.889
Apolipoprotein (a) (g/L)	1.27 (1.15-1.41)	1.28 (1.15-1.42)	1.27 (1.11- 1.41)	0.283
Apolipoprotein (b) (g/L)	1.03 (0.84-1.24)	1.01 (0.85-1.24)	1.02 (0.86- 1.21)	0.936
Lipoprotein (a) (mg/dL)	29.85 (11.50- 80.83)	24.85 (10.48- 72.50)	23.00 (8.10- 73.20)	0.174
Fibrinogen (mg/dL)	3.26 (2.89-3.68)	3.25 (2.84-3.74)	3.28 (2.93-	0.909

			2.70)	
Hs-CRP (mg/L)	1.44 (0.61-3.83)	1.84 (0.72-4.22)	1.41 (0.59-4.12)	0.509
Fasting glucose (mmol/L)	5.72 (5.11-7.86)	5.31 (4.82-6.85)	5.36 (4.88-6.63)	<0.001
Creatinine (µmol/L)	53.00 (47.00-59.00)	57.00 (50.00-63.00)	59.00 (52.50-67.00)	<0.001
Uric acid (µmol/L)	261.00 (220.00-316.00)	266.00 (228.00-318.00)	284.00 (236.5-334.00)	0.001
Coronary angiography findings, No. (%)				
Number of disease vessel				0.111
Normal	23 (6.1)	21 (5.8)	20 (5.5)	
One-vessel disease	159 (42.5)	147 (40.6)	158 (43.2)	
Two-vessel disease	93 (24.9)	102 (28.2)	70 (19.1)	
Three-vessel disease	99 (26.5)	92 (25.4)	118 (32.2)	
Location of artery lesion				
LM	19 (5.1)	7 (1.9)	14 (3.8)	0.072
LAD	109 (29.1)	133 (36.7)	131 (25.8)	0.059
LCX	52 (13.9)	48 (13.3)	41 (11.2)	0.518
RCA	62 (16.6)	53 (14.6)	61 (16.7)	0.701
Treatment, No. (%)				
CABG	17 (4.5)	14 (3.9)	28 (7.7)	0.053
PCI	183 (48.9)	181 (50.0)	192 (52.5)	0.617
Thrombolytic therapy	174 (46.5)	167 (46.1)	146 (39.9)	0.127
Drugs used after surgery, No. (%)				
Aspirin	356 (95.2)	345 (95.3)	348 (95.1)	0.990
Clopidogrel	245 (65.5)	236 (65.2)	238 (65.0)	0.990
Statins	340 (90.9)	334 (92.3)	333 (91.5)	0.803
Nitrate	154 (41.2)	146 (40.3)	168 (45.9)	0.260
ACEI	164 (43.9)	150 (41.4)	153 (41.8)	0.774
Beta blocker	261 (69.8)	235 (64.9)	231 (63.1)	0.140
Calcium antagonist	93 (24.9)	116 (32.0)	107 (29.2)	0.095

Comparison was determined by one-way analysis of variance (ANOVA), Chi-square test or Kruskal-Wallis H rank sum test. Hcy, homocysteine; SD, standard deviation; UA, unstable angina; NSTEMI, non-ST-elevation myocardial infarction; STEM, ST-elevation myocardial infarction; CHD, coronary heart disease; OMI, old myocardial infarction; PCI, percutaneous transluminal coronary intervention; CABG, coronary artery bypass grafting; LEVEF, left

ventricular ejection fraction; IQR, interquartile range; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LM, Left main; LAD, left anterior descending branch; LCX, left circumflex artery; RCA, right coronary artery; ACEI, angiotensin converting enzymes inhibitor.

Table 3 MACE across tertiles according to Hcy level

Items	Total patients	Lowest tertile (≤ 9.1 $\mu\text{mol/L}$)	Middle tertile (9.2-11.6 $\mu\text{mol/L}$)	Highest tertile (> 11.6 $\mu\text{mol/L}$)	<i>P</i> value
No.	1102	374	362	366	
UA alone, No. (%)	100 (9.1)	8 (2.1)	24 (6.6)	68 (18.6)	<0.001
AMI alone, No. (%)	10 (0.9)	1 (0.3)	2 (0.6)	7 (1.9)	0.042
UA and AMI, No. (%)	6 (0.5)	0 (0.0)	1 (0.3)	5 (1.4)	0.029
Cardiac death, No. (%)	2 (0.2)	0 (0.0)	1 (0.3)	1 (0.3)	0.598
MACE incidence, No. (%)	118 (10.7)	9 (2.4)	28 (7.7)	81 (22.1)	<0.001

Comparison was determined by Chi-square test. Hcy, homocysteine; UA, unstable angina; AMI, acute myocardial infarction; MACE, major adverse cardiovascular events.

Table 4 Univariate and multivariate Cox's proportional hazard regression model analyses of factors predicting MACE-free survival

Items	Univariate Cox's regression		Multivariate Cox's regression	
	<i>P</i> value	HR (95%CI)	<i>P</i> value	HR (95%CI)
Hcy				
Lowest tertile	-	Reference	-	Reference
Middle tertile	0.003	3.160 (1.491-6.698)	0.001	3.615 (1.661-7.864)
Highest tertile	<0.001	9.441 (4.739-18.807)	<0.001	11.023 (5.356-22.684)
Age	0.857	1.005 (0.955-1.057)	0.820	1.007 (0.950-1.068)
Diagnosis				
UA	-	Reference	-	Reference
NSTEMI	0.008	2.434 (1.266-4.680)	0.047	2.115 (1.009-4.434)
STEMI	0.896	1.037 (0.601-1.790)	0.884	0.948 (0.464-1.938)
Smoke	0.038	1.533 (1.025-2.294)	0.188	1.338 (0.867-2.064)
Hypertension	0.959	0.990 (0.676-1.451)	0.289	0.761 (0.460-1.261)
Diabetes	0.082	1.390 (0.959-2.015)	0.055	1.646 (0.990-2.735)
Family history of CHD	0.813	1.054 (0.681-1.631)	0.996	0.999 (0.632-1.578)
History of stroke	0.781	1.096 (0.573-2.097)	0.829	0.924 (0.452-1.887)
History of OMI	0.209	1.631 (0.760-3.503)	0.462	1.413 (0.563-3.545)
History of PCI	0.331	1.331 (0.748-2.369)	0.516	1.248 (0.639-2.439)
History of CABG	0.778	1.327 (0.185-9.516)	0.859	0.829 (0.106-6.500)
LVEF	0.415	0.990 (0.966-1.014)	0.450	1.013 (0.980-1.047)
HDL	0.052	0.516 (0.265-1.007)	0.052	0.200 (0.039-1.012)
LDL	0.383	0.919 (0.760-1.111)	0.309	0.681 (0.326-1.426)
VLDL	0.667	1.093 (0.730-1.635)	0.139	0.448 (0.155-1.298)
Triglyceride	0.520	1.046 (0.912-1.199)	0.616	1.094 (0.770-1.556)
Apolipoprotein (a)	0.297	0.632 (0.266-1.498)	0.195	3.521 (0.525-23.610)
Apolipoprotein (b)	0.679	0.875 (0.466-1.645)	0.571	2.122 (0.157-28.675)
Lipoprotein (a)	0.777	1.000 (0.997-1.002)	0.914	1.000 (0.997-1.002)
Fibrinogen	0.246	1.154 (0.906-1.469)	0.755	0.957 (0.725-1.262)
Hs-CRP	0.136	1.005 (0.999-1.011)	0.044	1.009 (1.000-1.019)
Fasting glucose	0.302	1.033 (0.971-1.098)	0.948	0.997 (0.912-1.089)
Creatinine	0.024	1.014 (1.002-1.026)	0.995	1.000 (0.984-1.016)
Uric acid	0.577	1.001 (0.998-1.003)	0.576	0.999 (0.997-1.002)
Number of disease vessel				
Normal	-	Reference	-	Reference
One-vessel disease	0.923	1.043 (0.444-2.451)	0.384	0.661 (0.260-1.678)
Two-vessel disease	0.663	1.217 (0.504-2.940)	0.326	0.608 (0.225-1.643)
Three-vessel disease	0.324	1.540 (0.653-3.634)	0.405	0.647 (0.232-1.803)

Location of artery lesion				
LM vs. others	0.122	1.828 (0.850-3.931)	0.130	1.927 (0.825-4.503)
LAD vs. others	<0.001	1.975 (1.372-2.844)	0.644	1.153 (0.629-2.115)
LCX vs. others	0.998	1.001 (0.589-1.699)	0.428	0.767 (0.398-1.478)
RCA vs. others	0.151	1.398 (0.885-2.207)	0.426	0.777 (0.417-1.447)
Treatment				
Thrombolytic therapy	-	Reference	-	Reference
CABG	0.013	2.583 (1.222-5.459)	0.078	2.303 (0.910-5.830)
PCI	<0.001	2.639 (1.724-4.040)	0.018	2.696 (1.184-6.139)
Drugs used after surgery				
Aspirin	0.703	1.261 (0.383-4.155)	0.488	1.557 (0.445-5.441)
Clopidogrel	0.008	1.812 (1.171-2.804)	0.986	1.006 (0.509-1.990)
Statins	0.605	1.234 (0.557-2.731)	0.901	1.055 (0.452-2.461)
Nitrate	0.910	1.021 (0.707-1.475)	0.518	0.873 (0.578-1.319)
ACEI	0.317	0.826 (0.568-1.201)	0.545	0.871 (0.557-1.363)
Beta blocker	0.192	1.313 (0.872-1.976)	0.154	1.363 (0.891-2.085)
Calcium antagonist	0.489	1.151 (0.772-1.715)	0.197	1.363 (0.851-2.184)

MACE, major adverse cardiovascular events; HR, hazard ratio; CI, confidence; Hcy, homocysteine; UA, unstable angina; NSTEMI, non-ST-elevation myocardial infarction; STEM, ST-elevation myocardial infarction; CHD, coronary heart disease; OMI, old myocardial infarction; PCI, percutaneous transluminal coronary intervention; CABG, coronary artery bypass grafting; LEVEF, left ventricular ejection fraction; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very low-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LM, Left main; LAD, left anterior descending branch; LCX, left circumflex artery; RCA, right coronary artery; ACEI, angiotensin converting enzymes inhibitor.

Figures




Figure 1

The effect of Hcy on MACE risk and MACE-free survival. A: The comparison of Hcy level between MACE patients and non-MACE patients. B: The predictive value of Hcy level for MACE risk. C: The correlation of Hcy level with MACE-free survival. Comparison of Hcy level between patients with MACE and patients without MACE was determined by the Wilcoxon rank sum test. The predictive value of Hcy level for MACE risk was assessed by the ROC curve and the derived AUC. The MACE-free survival was displayed by the Kaplan-Meier curves and was compared by the log-rank test among tertile groups. Hcy: homocysteine; MACE: major adverse cardiovascular events; ROC: receiver operating characteristic; AUC: area under the curve